Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
Valentina Nardi(Biopredic (France)), Dora Dias‐Santagata(Harvard University), Keith T. Flaherty(Cancer Research Center), Lori J. Wirth(Massachusetts General Hospital), Johanna C. Bendell(Dana-Farber Cancer Institute), Kristin Bergethon(Massachusetts General Hospital), Donald P. Lawrence(Massachusetts General Hospital), Peter M. Sadow(Massachusetts Eye and Ear Infirmary), A. John Iafrate(Massachusetts General Hospital), Rebecca S. Heist(Massachusetts General Hospital), Arjola K. Cosper(Massachusetts Eye and Ear Infirmary), Sihai Dave Zhao(Massachusetts Eye and Ear Infirmary), Dejan Juric(Massachusetts General Hospital), Vanessa Scialabba(Massachusetts Eye and Ear Infirmary), Yi Li(Nanyang Technological University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Daniel G. Deschler(Ludwig-Maximilians-Universität München), Julie M. Batten(Massachusetts Eye and Ear Infirmary)
Cited by 112
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k